Femasys Inc (FEMY)vsMedline Inc. Class A Common Stock (MDLN)
FEMY
Femasys Inc
$0.51
-0.06%
HEALTHCARE · Cap: $33.17M
MDLN
Medline Inc. Class A Common Stock
$42.67
+1.52%
HEALTHCARE · Cap: $34.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 1379090% more annual revenue ($28.43B vs $2.06M). MDLN leads profitability with a 4.1% profit margin vs 0.0%. MDLN earns a higher WallStSmart Score of 52/100 (C-).
FEMY
Avoid23
out of 100
Grade: F
MDLN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FEMY.
Margin of Safety
+32.7%
Fair Value
$66.92
Current Price
$42.67
$24.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 31.4% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -3.8% — below average capital efficiency
Moderate valuation
ROE of 6.5% — below average capital efficiency
4.1% margin — thin
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : FEMY
The strongest argument for FEMY centers on Revenue Growth. Revenue growth of 31.4% demonstrates continued momentum.
Bull Case : MDLN
Revenue growth of 14.8% demonstrates continued momentum.
Bear Case : FEMY
The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
FEMY profiles as a hypergrowth stock while MDLN is a value play — different risk/reward profiles.
FEMY is growing revenue faster at 31.4% — sustainability is the question.
FEMY generates stronger free cash flow (-6M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDLN scores higher overall (52/100 vs 23/100) and 14.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Femasys Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Femasys Inc. is an innovative medical technology firm at the forefront of transforming women's healthcare through its proprietary solutions aimed at diagnosing and treating gynecological conditions. The company is particularly recognized for its flagship products that offer non-surgical alternatives for common issues such as uterine fibroids and contraception, positioning it as a leader in the evolving landscape of women's health. As demand for minimally invasive procedures grows, Femasys is strategically positioned to capitalize on this trend, enhancing patient outcomes while optimizing healthcare delivery. With a commitment to addressing significant unmet needs in women's health, Femasys aims to revolutionize the standards of care in this vital sector.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?